The expiry of Novo Nordisk’s patent on semaglutide in India marks a watershed moment in the country’s pharmaceutical and public health landscape. As the active ingredient behind globally dominant drugs such as Ozempic and Wegovy enters the generic domain, India stands on the brink of a profound market transformation. What appears at first glance to be a triumph of affordability and access is, on closer examination, a complex convergence of intellectual property law, regulatory capacity, market dynamics, and public health risk. The entry of more than 40 domestic pharmaceutical companies, expected to launch over 50 branded generics within weeks, signals not merely competition but a structural shock to an already fragmented and price-sensitive healthcare ecosystem.
At the heart of this development lies the expiration of patent protection, a legal mechanism designed to balance innovation incentives with eventual public access. Under India’s intellectual property regime, once a patent lapses, the exclusive right of the originator to manufacture and sell the drug ceases, opening the field to generic manufacturers. In this instance, the expiration of the patent on semaglutide effectively dismantles Novo Nordisk’s monopoly in one of the fastest-growing therapeutic segments globally. Indian pharmaceutical companies including Sun Pharma, Dr. Reddy’s Laboratories, Zydus Lifesciences, Lupin Limited, Alkem Laboratories and Mankind Pharma are poised to capitalise on this opening. However, while patent expiry permits market entry, it does not dilute the obligation to comply with India’s regulatory framework governing safety, efficacy, and quality. The critical question, therefore, is not whether generics can enter the market, but whether the regulatory ecosystem can adequately supervise their proliferation.
The most immediate and visible impact of generic entry is price erosion. Estimates suggest that monthly treatment costs, previously around 11,000 rupees for lower doses, could fall to between 3,000 and 5,000 rupees in the near term, and potentially as low as 1,500 to 2,500 rupees over time. This dramatic reduction is likely to expand access beyond a narrow urban demographic to a much broader patient base. In a country with one of the highest burdens of diabetes and a rapidly rising prevalence of obesity, the implications are significant. By 2050, projections indicate that over 440 million individuals in India could fall within the overweight or obese category, creating sustained demand for pharmacological interventions. From a market perspective, this positions semaglutide generics as a cornerstone of a rapidly expanding obesity drug market, projected to grow from approximately 15 billion rupees to 80 billion rupees by 2030.
Yet, the expansion of access is accompanied by equally significant risks. Semaglutide is a prescription drug with a specific dosing regimen and well documented side effect profile. Its safe use requires medical supervision, gradual titration, and continuous monitoring. India’s regulatory enforcement, however, has historically struggled with consistency, particularly in relation to prescription only medicines. The anticipated influx of low cost generics raises concerns about off label use, direct pharmacy sales without adequate oversight, and the potential for widespread misuse, particularly in urban markets where demand for weight loss solutions is high. The risk is not merely theoretical. Analysts have already flagged the possibility of “lifestyle use” and cosmetic consumption, which may lead to improper dosing, unmanaged adverse effects, and eventual regulatory backlash. In such a scenario, the burden of harm may shift not only to patients but also to prescribers, pharmacists, and manufacturers, raising complex questions of liability.
The Indian pharmaceutical market is uniquely physician driven, with prescribing behaviour playing a decisive role in determining commercial success. In the case of semaglutide generics, the sheer volume of new entrants is likely to create an initial phase of confusion and fragmentation. Brand proliferation, particularly where multiple products adopt similar naming conventions, may further complicate clinical decision making. Over time, it is expected that physician trust will consolidate around a limited number of manufacturers that demonstrate consistent quality, reliable supply chains, and effective delivery systems. This process of consolidation is likely to result in the exit of weaker players within two to three years, reinforcing the importance of quality differentiation in a price competitive environment.
The entry of generics also places significant pressure on originator companies and their global competitors. Novo Nordisk, along with Eli Lilly, which has recently introduced its own obesity drug Mounjaro in India, must now contend with a market where pricing power is rapidly eroding. While brand recognition and perceived quality may sustain a segment of demand, the scale of price differentials is likely to shift a substantial portion of the market towards generics. This dynamic reflects a broader trend in emerging markets, where affordability often outweighs brand loyalty in determining patient choice.
From a legal standpoint, the proliferation of semaglutide generics introduces heightened exposure to product liability and regulatory enforcement. In cases of adverse outcomes linked to misuse or substandard formulations, questions may arise regarding the adequacy of warnings, labelling, and distribution practices. Furthermore, the possibility of regulatory tightening cannot be discounted. Should misuse become widespread, authorities may be compelled to introduce stricter controls on prescription, distribution, and marketing. This could include enhanced pharmacovigilance requirements, tighter inspection regimes, and potential restrictions on over the counter availability. Such measures, while necessary from a public health perspective, may also reshape the competitive landscape, favouring larger, more compliant manufacturers over smaller entrants.
The expiry of semaglutide’s patent in India represents far more than a routine transition from monopoly to competition. It is a moment that encapsulates the enduring tension between access and accountability, affordability and safety, innovation and regulation. While the arrival of low cost generics promises to democratise access to life changing therapies, it simultaneously exposes the vulnerabilities of a regulatory system under strain. The ultimate trajectory of this market will depend not only on pricing dynamics, but on the ability of legal and regulatory institutions to ensure that expanded access does not come at the cost of patient safety. In this unfolding landscape, the real test is not whether generics can succeed, but whether the system governing them can keep pace with the speed and scale of change.